vs

Side-by-side financial comparison of MEDIFAST INC (MED) and SYNCHRONOSS TECHNOLOGIES INC (SNCR). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $42.0M, roughly 1.8× SYNCHRONOSS TECHNOLOGIES INC). On growth, SYNCHRONOSS TECHNOLOGIES INC posted the faster year-over-year revenue change (-2.2% vs -36.9%). SYNCHRONOSS TECHNOLOGIES INC produced more free cash flow last quarter ($39.0M vs $-6.6M). Over the past eight quarters, SYNCHRONOSS TECHNOLOGIES INC's revenue compounded faster (0.7% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Synchronoss Technologies Inc develops cloud-based digital transformation, subscriber management and messaging solutions for global telecom operators and enterprise clients. Its core offerings support connectivity onboarding, IoT service enablement, with key markets spanning North America, Europe and Asia-Pacific.

MED vs SNCR — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$42.0M
SNCR
Growing faster (revenue YoY)
SNCR
SNCR
+34.7% gap
SNCR
-2.2%
-36.9%
MED
More free cash flow
SNCR
SNCR
$45.6M more FCF
SNCR
$39.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
SNCR
SNCR
Annualised
SNCR
0.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
MED
MED
SNCR
SNCR
Revenue
$75.1M
$42.0M
Net Profit
$5.8M
Gross Margin
69.4%
79.4%
Operating Margin
-10.4%
14.0%
Net Margin
13.8%
Revenue YoY
-36.9%
-2.2%
Net Profit YoY
201.7%
EPS (diluted)
$-1.64
$0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SNCR
SNCR
Q4 25
$75.1M
Q3 25
$89.4M
$42.0M
Q2 25
$105.6M
$42.5M
Q1 25
$115.7M
$42.2M
Q4 24
$119.0M
$44.2M
Q3 24
$140.2M
$43.0M
Q2 24
$168.6M
$43.5M
Q1 24
$174.7M
$43.0M
Net Profit
MED
MED
SNCR
SNCR
Q4 25
Q3 25
$-2.3M
$5.8M
Q2 25
$2.5M
$-19.6M
Q1 25
$-772.0K
$-3.8M
Q4 24
$7.9M
Q3 24
$1.1M
$-5.7M
Q2 24
$-8.2M
$-494.0K
Q1 24
$8.3M
$4.5M
Gross Margin
MED
MED
SNCR
SNCR
Q4 25
69.4%
Q3 25
69.5%
79.4%
Q2 25
72.6%
79.0%
Q1 25
72.8%
79.4%
Q4 24
74.1%
78.6%
Q3 24
75.4%
79.1%
Q2 24
73.2%
76.1%
Q1 24
72.8%
76.2%
Operating Margin
MED
MED
SNCR
SNCR
Q4 25
-10.4%
Q3 25
-4.6%
14.0%
Q2 25
-1.0%
16.1%
Q1 25
-1.1%
19.5%
Q4 24
0.6%
16.5%
Q3 24
1.5%
12.8%
Q2 24
-4.7%
9.9%
Q1 24
4.5%
10.7%
Net Margin
MED
MED
SNCR
SNCR
Q4 25
Q3 25
-2.5%
13.8%
Q2 25
2.3%
-46.1%
Q1 25
-0.7%
-9.0%
Q4 24
17.8%
Q3 24
0.8%
-13.3%
Q2 24
-4.8%
-1.1%
Q1 24
4.8%
10.4%
EPS (diluted)
MED
MED
SNCR
SNCR
Q4 25
$-1.64
Q3 25
$-0.21
$0.51
Q2 25
$0.22
$-1.87
Q1 25
$-0.07
$-0.37
Q4 24
$0.08
$0.75
Q3 24
$0.10
$-0.56
Q2 24
$-0.75
$0.01
Q1 24
$0.76
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SNCR
SNCR
Cash + ST InvestmentsLiquidity on hand
$167.3M
$34.8M
Total DebtLower is stronger
$163.2M
Stockholders' EquityBook value
$198.9M
$55.4M
Total Assets
$248.0M
$278.2M
Debt / EquityLower = less leverage
2.95×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SNCR
SNCR
Q4 25
$167.3M
Q3 25
$173.5M
$34.8M
Q2 25
$162.7M
$24.6M
Q1 25
$164.6M
$29.1M
Q4 24
$162.3M
$33.4M
Q3 24
$170.0M
$25.2M
Q2 24
$163.5M
$23.6M
Q1 24
$156.4M
$19.1M
Total Debt
MED
MED
SNCR
SNCR
Q4 25
Q3 25
$163.2M
Q2 25
$186.2M
Q1 25
$187.0M
Q4 24
$186.7M
Q3 24
$186.4M
Q2 24
$186.2M
Q1 24
$136.6M
Stockholders' Equity
MED
MED
SNCR
SNCR
Q4 25
$198.9M
Q3 25
$214.7M
$55.4M
Q2 25
$216.0M
$49.4M
Q1 25
$211.0M
$35.4M
Q4 24
$210.1M
$29.8M
Q3 24
$207.3M
$35.3M
Q2 24
$205.3M
$30.6M
Q1 24
$211.0M
$24.0M
Total Assets
MED
MED
SNCR
SNCR
Q4 25
$248.0M
Q3 25
$268.2M
$278.2M
Q2 25
$269.3M
$291.4M
Q1 25
$280.0M
$293.3M
Q4 24
$284.2M
$293.8M
Q3 24
$291.2M
$299.7M
Q2 24
$293.5M
$295.7M
Q1 24
$302.8M
$298.5M
Debt / Equity
MED
MED
SNCR
SNCR
Q4 25
Q3 25
2.95×
Q2 25
3.77×
Q1 25
5.28×
Q4 24
6.27×
Q3 24
5.28×
Q2 24
6.08×
Q1 24
5.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SNCR
SNCR
Operating Cash FlowLast quarter
$-5.3M
$39.4M
Free Cash FlowOCF − Capex
$-6.6M
$39.0M
FCF MarginFCF / Revenue
-8.8%
92.9%
Capex IntensityCapex / Revenue
1.8%
0.9%
Cash ConversionOCF / Net Profit
6.77×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$53.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SNCR
SNCR
Q4 25
$-5.3M
Q3 25
$12.1M
$39.4M
Q2 25
$-3.4M
$2.3M
Q1 25
$3.4M
$293.0K
Q4 24
$-4.9M
$13.1M
Q3 24
$9.1M
$3.4M
Q2 24
$13.1M
$11.3M
Q1 24
$7.3M
$527.0K
Free Cash Flow
MED
MED
SNCR
SNCR
Q4 25
$-6.6M
Q3 25
$10.8M
$39.0M
Q2 25
$-4.8M
$2.0M
Q1 25
$1.9M
$-31.0K
Q4 24
$-7.2M
$12.2M
Q3 24
$7.7M
$3.2M
Q2 24
$11.1M
$10.9M
Q1 24
$5.4M
$10.0K
FCF Margin
MED
MED
SNCR
SNCR
Q4 25
-8.8%
Q3 25
12.0%
92.9%
Q2 25
-4.5%
4.6%
Q1 25
1.6%
-0.1%
Q4 24
-6.1%
27.6%
Q3 24
5.5%
7.5%
Q2 24
6.6%
25.2%
Q1 24
3.1%
0.0%
Capex Intensity
MED
MED
SNCR
SNCR
Q4 25
1.8%
Q3 25
1.5%
0.9%
Q2 25
1.3%
0.8%
Q1 25
1.3%
0.8%
Q4 24
1.9%
1.9%
Q3 24
1.0%
0.3%
Q2 24
1.1%
0.9%
Q1 24
1.1%
1.2%
Cash Conversion
MED
MED
SNCR
SNCR
Q4 25
Q3 25
6.77×
Q2 25
-1.36×
Q1 25
Q4 24
1.66×
Q3 24
8.04×
Q2 24
Q1 24
0.88×
0.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

SNCR
SNCR

Subscription Services$39.4M94%
Professional Services$2.6M6%

Related Comparisons